Caribou Biosciences (NASDAQ:CRBU) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Caribou Biosciences (NASDAQ:CRBU) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $9.00 price objective on the stock.

Other equities analysts also recently issued research reports about the company. Bank of America lowered their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Citigroup lowered their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 26th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Stock Performance

NASDAQ:CRBU opened at $0.95 on Wednesday. The stock’s 50-day simple moving average is $1.32 and its 200 day simple moving average is $1.75. The company has a market cap of $88.44 million, a P/E ratio of -0.58 and a beta of 2.34. Caribou Biosciences has a 52-week low of $0.95 and a 52-week high of $5.77.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The firm had revenue of $2.08 million for the quarter, compared to the consensus estimate of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. As a group, equities analysts predict that Caribou Biosciences will post -1.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Caribou Biosciences

Institutional investors have recently made changes to their positions in the company. Centric Wealth Management bought a new stake in shares of Caribou Biosciences during the fourth quarter worth approximately $27,000. Erste Asset Management GmbH bought a new stake in shares of Caribou Biosciences in the third quarter valued at approximately $28,000. Russell Investments Group Ltd. boosted its stake in shares of Caribou Biosciences by 859.0% in the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock valued at $38,000 after buying an additional 21,416 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Caribou Biosciences by 60.0% in the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock valued at $39,000 after buying an additional 9,148 shares during the period. Finally, Diametric Capital LP bought a new stake in shares of Caribou Biosciences in the fourth quarter valued at approximately $42,000. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.